Fintech And Biotech Are Coming Together To Transform Drug Development

资本助力生物制药公司,提高效率改变药物开发环境

2019-01-30 17:46:22 Forbes

本文共834个字,阅读需3分钟

Agenus, Inc. has announced the launch of the Biotech Electronic Security Token (BEST), a new, blockchain-based digital security to finance a single biotech asset alongside traditional financing for institutional and individual investors.  The initial asset to be tokenized is AGEN2034, a PD-1 inhibitor and a member of a class of drugs generating over $15 billion in revenue in 2018. Not only a bold step, this is fundamental change for the bio-pharmaceutical industry that can have broad-reaching implications.   The allocation of capital invested in drug development is estimated to have exceed $150 billion in 2017. Yet developement remains problematic on many fronts. In the traditional model, the valuation of an individual asset remains a function of the entire company's portfolio and the resulting dilution. Further, frequent restriction of promising investments to institutional inventors came limited access to a variety of parties from payors to patients. The resulting inefficiencies in investments can complicate, obstruct and impede multiple aspect of drug development. However, this new approach taken by Agenus establishes unique solutions to "tokenize" a portion of future US asset sales and offer key advantages: Simply put, the depth and breadth of financing has changed by this new mechanism.  And interestingly, this evolving "democratization" of drug development financing mirrors today's health tech environment where clinical control is shifting to a more collaborative dynamic. Leveraging blockchain, Agenus can not only target a single biotech asset, but can establish new and powerful advantages from risk mitigation to a sharpened strategic focus. The establishment of this "open source" financing can become a fundamental shift to a more open and inclusive option across socioeconomic barriers. Further, the intrinsic security and organizational infrastructure may create a higher level of trusted, end to end financing. The impact of technology in the life sciences industry is significant. From biotechnology and immunotherapy to the empowerment of consumers to play a more, proactive role is care, these changes are at the heart of disruption to system that, by many standards, is broken. The "tokenization" of drug development financing is a unique and emerging option that may be about more than just money. The newfound focus on an individual drug asset combined with the a blockchain-based digital security may drive a new level of participation.  Patients, advocacy groups, payors, clinicians, and a host of other stakeholders, in combination with traditional investors, may now invests in a drug therapy where a powerful emotional investment may have already taken place.
Agenus , Inc .宣布推出生物技术电子安全令牌( BEST ),这是一种基于区块链的新型数字证券,除了为机构和个人投资者提供传统融资之外,还为单一生物技术资产提供融资。将予标记的初始资产是 AGN2034,一种 PD-1抑制剂,以及一类药物的成员,该药物在2018年产生了超过150亿美元的收入。这不仅是一个大胆的步骤,这是对生物制药行业的根本改变,可以有广泛的影响。 2017年药品研发投入的资金分配预计超过1500亿美元。然而,发展在许多方面仍然存在问题。在传统模型中,单个资产的估值仍然是整个公司投资组合的函数,并由此产生的摊薄。此外,经常限制对机构投资者有前途的投资的做法,也限制了从付款人到患者等各方的接触。 由此造成的投资效率低下可能使药物开发的多个方面复杂化、阻碍和妨碍。然而, Agenus 采用的这种新方法为“标记”未来美国资产销售的一部分建立了独特的解决方案,并提供了关键优势: 简单地说,这种新机制改变了融资的深度和广度。有趣的是,药物开发融资的这种不断演变的“民主化”反映了当今的卫生技术环境,临床控制正在向更具协作性的动态转变。利用区块链, Ageuns 不仅可以针对单一的生物技术资产,而且可以建立新的和强大的优势,从风险缓解到锐化的战略重点。建立这一"开放来源"融资,可以成为社会经济障碍中更加开放和包容的选择的根本转变。此外,内在的安全和组织基础设施可以创建更高级别的可信端到端融资。 技术对生命科学行业的影响是显著的。从生物技术和免疫疗法到赋予消费者更多的权力,积极主动的作用是照顾,这些变化是破坏系统的核心,按许多标准来说,是被打破的。药物开发融资的“代币化”是一个独特的和新兴的选择,可能不仅仅是钱。新发现的对单个药物资产的关注与基于区块链的数字安全相结合,可能会推动新的参与水平。患者、倡导团体、支付者、临床医生和许多其他利益相关者,连同传统的投资者,现在可能会投资于一种药物治疗,在那里可能已经发生了强大的情感投资。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文